Title: Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy
Abstract: Immune checkpoint inhibitors are new drugs approved for the treatment of many types of malignancies, such as lung cancer, melanoma and renal cancer. These monoclonal antibodies are directed against inhibitory immune receptors Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) (ipilimumab) and programmed cell death 1 (PD-1; nivolumab and pembrolizumab) and can improve the immune function of T-cells, resulting in significant clinical benefit in multiple cancer types. Despite their wide use and unquestionable clinical benefits, these agents have been also associated with a unique spectrum of side-effects known as immune-related adverse events (irAEs) [ [1] Topalian S.L. Hodi F.S. Brahmer J.R. Connell L.C. Schindler K. Lacouture M.E. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015; 26: 2375-2391 Abstract Full Text Full Text PDF PubMed Scopus (909) Google Scholar ]. The most common cutaneous irAEs are general maculopapular rashes, pruritus and lichenoid skin reaction, but several uncommon toxicities have been reported. We report a case of bullous pemphigoid (BP) triggered during nivolumab therapy in a patient affected by non–small-cell lung cancer (NSCLC).
Publication Year: 2018
Publication Date: 2018-11-01
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 21
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot